semaglutide approved for cardiovascular tops dulaglutide when treating patients with type 2 diabetes and CVD Wegovy® receives FDA approval for

Morffy and Strader, 2020)

Molecular Profiles of the BPC-157 and TB-500 Peptides BPC-157 TB-500 (Thymosin Beta-4) Storage, Handling, and Reconstitution of the BPC-157 + TB-500 Peptide Blend Store the lyophilized vial at -20 C (-4 F), sealed and protected from light and moisture

According to clinical trial data and the Summary of Product Characteristics (SmPC) approved by the MHRA, the most frequently reported adverse effects include: Nausea (affecting up to 44% of patients) Diarrhoea (approximately 30% of patients) Vomiting (24% of patients) Constipation (24% of patients) Abdominal pain (20% of patients) Dyspepsia (indigestion) Flatulence and bloating These gastrointestinal symptoms typically occur early in treatment and often improve over time as the body adjusts to the medication

, GLP-1